/ /

  • linkedin
  • Increase Font
  • Sharebar

    TCP gains traction as modality for glaucoma cases with good visual potential

    Refining laser delivery improves safety for procedures; allows for earlier intervention



    When used to treat most patients that had good visual potential, TCP was effective and safe; mTCP is even more so.

    The MicroPulse P3 device has changed current thinking about cyclophotocoagulation in that it offers another option in the glaucoma treatment algorithm and allows for earlier laser intervention when medical treatment comes up short.


    Robert J. Noecker, MD, MBA

    E: [email protected]

    Dr. Noecker is in practice with Ophthalmic Consultants of Connecticut, Fairfield, CT, and is assistant clinical professor, Yale University School of Medicine, New Haven, CT.


    1. Caprioli J, Strang SL, Spaeth GL. Cyclocryotherapy in the treatment of advanced glaucoma. Ophthalmology. 1985;92:947–954.
    2. Benson MT, Nelson ME. Cyclocryotherapy: a review of cases over a 10 year period. Br J Ophthalmol. 1990;74:103–105.
    3. Ansari E, Gandhewar J. Long-term efficacy and visual acuity following transscleral diode laser photocoagulation in cases of refractory and non-refractory glaucoma. Eye. 2007;21:936-940.
    4. Arjamaa O, Nikinmaa M. Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp Eye Res. 2006;83:473-483.
    5. Radcliffe N, Vold S, Kammer J, et al. MicroPulse trans-scleral cyclophotocoagulation (mTSCPC) for the treatment of glaucoma using the MicroPulse P3 device. Poster presented at the American Glaucoma Society annual Meeting. April 2015.
    Robert J. Noecker, MD
    Dr. Noecker, vice chair, University of Pittsburgh Medical Center Eye Center, and director, Glaucoma Service and associate professor of ...

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results